New data at american foregut society's 2025 annual meeting demonstrates tissuecypher® can detect high-risk barrett's esophagus patients not identified by pathology to support improved care decisions

Friendswood, texas, sept. 09, 2025 (globe newswire) -- castle biosciences, inc. (nasdaq: cstl), a company improving health through innovative tests that guide patient care, today announced that new data demonstrating the personalized risk stratification provided by its tissuecypher barrett's esophagus test will be shared via a podium presentation at the american foregut society's (afs) 2025 annual meeting, taking place sept.
CSTL Ratings Summary
CSTL Quant Ranking